1. Main diagnosis of RA (using relevant ICD-10 codes according to Table 1) , and/or 2. Treatment with approved biological agent for RA at least for three months
l If the diagnosis occurred before 2012 patients were only selected if they were already on treatment at the beginning of the observation period in 2012.
l The relevant patient sample was then split into three groups with regard to the observation period from 2012 to 2016:
1. Patients who start a biological treatment ("New")
2. Patients who get continuous treatment with the same biological ("Repeater")
3. Patients who switch biological ("Switcher")
l In sum, 4'233 patients could be included in the sample.
l The study evaluated direct medical costs (drugs, outpatient care and hospital admission), hospital admission and change in medication.
l Treatment costs included costs for biological agents which were approved for the treatment of RA (as of April 2017, see also Table 2 ). Furthermore, the following medication groups were considered to be RA related (see also l In case that a patient changed therapy during the observation period, he was further included only if he continued receiving a biological agent.
l Figure 1 depicts an overview of the analysis of the sample. 
Aminosalicylic acid and similar agents

A07EC01 -A07EC04
Selective immunosuppressants L04AA06
Non-steroidal antiinflammatory drugs 
RESULTS:
l Most patients with RA are aged above 46, thereby the proportion below 17 years' account for less than 2%. The average age of all age cohorts is 54.8 years, with the subgroup of men slightly younger than women (53.8 yr men vs. 55.2 yr women).
l The proportion of women is more than twice as high as of men (68.5% male vs 31.5% female) (see also Figure 2 ). l Figure 3 shows the yearly treatment cost of patients over the time period. The total costs add up to € 78'202'566 in 2015 and the total treatment cost grew yearly on average by 11.3% from 2012 to 2015. The total number of patients grew yearly on average by 10.0% from 2012-2015. As expected, the key cost driver were biological agents which account for 80.6% of total cost (in 2015). The costs could be slightly overestimated due to potential intersections of patients who begin, repeat or switch the therapy. With regard to 2016, comprehensive data sets only exist for Q1/2016 and Q2/2016, data from Q3/2016 is incomplete. This has to be taken into account when interpreting the data. 
CONCLUSIONS:
l Etanercept and adalimumab are those biological agents mainly used in Germany by patients who are already on treatment.
l Costs grew steadily over the last four years. Hereby, the key cost driver were the biological agents.
l Total costs in 2015 were € 78.2 million and on average € 18'475 per patient.
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